New Mexico aims to enroll its first medical psilocybin patients by December, with a certifying clinician determining who qualifies
Four qualifying conditions, a clinician's judgment at the door, and draft rules still deciding which clinicians count.
THE DISPATCH
New Mexico's Department of Health says it aims to enroll the state's first medical psilocybin patients by the end of December 2026, roughly a year ahead of the statutory deadline of December 31, 2027.¹ ² If that goal is met, New Mexico will be operating a state psilocybin program built on a medical model: a defined list of qualifying conditions, and a certifying clinician who must judge each patient to be a medically appropriate candidate before treatment.² That is a different design from Oregon's adult-access program, examined in this newsletter on October 2, which does not require a prescription or medical referral.³ The U.S. policy landscape around psilocybin has changed rapidly over the past several years, with state-regulated access models developing alongside the traditional FDA drug-development pathway.
In this issue:
→ What New Mexico's law requires, and what its draft clinician rules are still deciding
→ Why a program that gives PTSD patients a path in still leaves many veterans' own clinicians outside it
→ Oregon drops a proposed licensing fee increase, and FDA's drug center gets a permanent director with psychedelic drug development experience
THE SCIENCE
Senate Bill 219, the Medical Psilocybin Act, was signed in April 2025 and took effect on June 20, 2025.¹ It names four qualifying conditions: major treatment-resistant depression, posttraumatic stress disorder, substance use disorders, and end-of-life care, plus any other conditions the department approves.² A nine-member Medical Psilocybin Advisory Board reviews those conditions and hears petitions to add new ones.² The act defines a qualified patient as one whose clinician has judged them a medically appropriate candidate on the basis of a qualifying diagnosis.² The program separates medical eligibility determination from treatment delivery: a qualified patient must first be judged medically appropriate by a certifying clinician, while preparation, administration, and integration occur within approved settings under the program's regulated practitioner and facilitator framework.² ⁴ The act does not provide for home use. It also creates a treatment equity fund for patients who meet income requirements set by department rule, and a $1 million research fund for state universities and health care providers studying medical uses of psilocybin.²
Implementation has moved from statute to operations this year. The department opened permit applications for psilocybin producers on August 17, 2026.⁵ Program psilocybin will come from mushrooms cultivated by state-permitted producers, and the production rule the department proposed this spring is written around mushroom cultivation, harvesting, and laboratory testing.⁶ The federal picture is unchanged: psilocybin remains a Schedule I controlled substance under federal law, and the act protects participants from state prosecution only.² Many contemporary FDA-regulated clinical trials, including those of synthetic psilocybin (COMP360), use a standardized synthetic formulation under a defined research protocol. The rules governing certifying clinicians, practitioners, facilitators, and healing centers (7.35.3 NMAC) remain in draft. Public comment filed with the department describes a transitional pathway under which experienced clinicians applying by December 31, 2027 could document at least 40 hours of psilocybin-related contact time in place of the full New Mexico practicum.⁴ The department scheduled a public hearing on the draft rules for October 2 in Santa Fe.⁴ ⁷
The clinical significance of this design lies in where the screening decision sits. New Mexico places formal medical candidacy determination with a licensed certifying clinician, whereas Oregon's adult-access model does not require a prescription or medical referral and conducts eligibility screening within the facilitator-led preparation process, where a client can be deemed ineligible for ideation of harm to self or others, lithium use within 30 days, or a diagnosis of active psychosis.³ That difference matters because the patients most likely to seek treatment for treatment-resistant depression or PTSD are often not the carefully selected, medically uncomplicated volunteers who make up most psilocybin trial populations. This becomes particularly important for patients with medical or psychiatric complexity, including cardiovascular or cerebrovascular disease, seizure disorders, neurodegenerative disease, substantial polypharmacy, bipolar-spectrum illness, or vulnerability to psychosis. Many such patients have been excluded or underrepresented in controlled psychedelic trials, leaving clinicians with substantially less evidence on which to base individualized risk-benefit decisions. The issue is especially relevant for patients with cardiovascular or cerebrovascular disease, because psilocybin can transiently increase blood pressure and, less consistently, heart rate. A 2026 review of supervised studies reported mean increases of about 19 mmHg systolic and 9 mmHg diastolic, peaking 60 to 90 minutes after dosing and generally resolving within four to six hours, while patients at higher vascular risk have generally been underrepresented in those trials.⁸ A certifying clinician does not create evidence that does not yet exist, but the design does create a defined point at which that judgment is made and, if the department collects program data as the act directs, recorded.²
The unsettled question is who will count as a certifying clinician. The proposed rules, as currently drafted, would limit certifying authority to clinicians who hold a state controlled substance registration, a provision that critics argue could narrow the pool of professionals able to certify patients, including licensed counselors who diagnose and treat PTSD.⁷ Because the rulemaking remains pending, the final eligibility requirements may still change. What any outcomes data from this program will be able to show is also worth stating now. Like Oregon's, it will be observational: longitudinal improvements following program participation, not estimates of psilocybin's treatment effect. Randomized controlled trials remain our strongest available design for estimating how much improvement is attributable to the intervention rather than natural symptom fluctuation, regression to the mean, expectancy, setting, and other nonspecific factors, although functional unblinding and expectancy remain important methodological challenges even in psychedelic RCTs.
THE STORY
PTSD is one of the four conditions the New Mexico act names, and veterans have been among the most visible advocates for access.² Federal restrictions create a particular obstacle for veterans receiving care through the VA, whose clinicians operate within a federal health system while psilocybin remains federally controlled.⁷ For a New Mexico veteran whose mental health care runs through the VA, the clinician who knows their history best may not be in a position to certify them for the state program. That gap comes from the structure of federal law rather than from any one agency. Forward motion is visible on the federal side. S.4220, the Veterans Health Administration Novel Therapeutics Preparedness Act, introduced on March 26, 2026, would create an Office of Novel Therapeutics within the VA, along with national clinical standards and training centers for emerging therapies.⁹ It is designed to prepare the VA for therapies that reach FDA approval and would not give veterans access to state programs.⁹ The American Legion endorsed the bill at its national convention, as reported on September 17.¹⁰ The bill remains in the Senate Committee on Veterans' Affairs, which held a hearing on it on April 29.⁹
Rose Hill Life Sciences is a psychedelic research organization, specializing in the production and research of Psilocybe cubensis operating at the intersection of science and therapeutic integration.
ON OUR RADAR
① Oregon Drops Its Proposed Psilocybin License Fee Increases
On September 22, 2026, the Oregon Health Authority said it will not move forward with proposed fee increases for psilocybin facilitators, manufacturers, service centers, and laboratories, citing input from its advisory board, rule advisory committees, and public comment.¹¹ The agency will open a separate rulemaking for unrelated program changes, with an anticipated effective date of January 15, 2027.¹¹
② A Second Breakthrough Designation for an LSD Formulation
On September 8, 2026, the FDA granted Breakthrough Therapy designation to Definium Therapeutics' DT120, an orally disintegrating tablet of lysergide, for major depressive disorder, following the company's reported Phase 3 Emerge results.¹² Those results have not yet appeared in a peer-reviewed journal, so this newsletter treats them as provisional. DT120 already held the same designation for generalized anxiety disorder.¹²
③ FDA's Drug Center Gets a Permanent Director With Psychedelic Development Experience
On September 8, 2026, HHS named Michael Davis, a psychiatrist who had led the Center for Drug Evaluation and Research on an acting basis since May, as its permanent director.¹³ Between December 2022 and June 2025, Davis served as chief medical officer of the Usona Institute, a nonprofit developing psilocybin for major depressive disorder.¹³
YOU ASKED
Q: "A patient in New Mexico asked me whether to wait for the state program or try to get into a clinical trial. How should I think about that?"
They answer different questions. Many contemporary FDA-regulated clinical trials use a standardized synthetic psilocybin formulation under a defined research protocol, with specified eligibility criteria and structured safety monitoring, and their results contribute to the evidence base on whether the treatment works. Eligibility is usually narrow, and many patients with medical complexity will not qualify. The state program operates under different eligibility criteria, uses mushroom-derived psilocybin under state law, and depends on an individualized determination of medical appropriateness rather than a research protocol. For a patient with cerebrovascular disease, a seizure disorder, bipolar-spectrum illness, or substantial polypharmacy, either pathway warrants careful individualized assessment of medical and psychiatric risk, potential drug interactions, and the limits of the available evidence. ClinicalTrials.gov is the place to check which trials are currently recruiting.
This week's takeaway: New Mexico is preparing to offer psilocybin through a medical model, with named qualifying conditions and a certifying clinician determining who is a medically appropriate candidate. The rules that define which clinicians can make that determination are still being finalized, and they will shape who the program actually reaches.
A question worth sitting with: if a medical model is meant to put careful screening at the front door, how should a state balance that protection against the risk that too few qualified clinicians are allowed to open the door at all?
Read the program details directly: New Mexico Department of Health: Medical Psilocybin Program
If a patient has asked you about psilocybin and you weren't sure where to point them, this is the source. Forward it to one colleague fielding the same question.
— Burton Tabaac
MD, Neurologist and Psychedelic Researcher
Advancing the development of novel psychedelic-based therapeutics
FOOTNOTES
¹ New Mexico Department of Health. "Medical Psilocybin Program." https://www.nmhealth.org/about/mcpp/mpp/ | New Mexico Department of Health, Center for Medical Cannabis and Psilocybin. Program information guide. https://www.nmhealth.org/publication/view/guide/9603/
² New Mexico Legislature. Senate Bill 219, "Medical Psilocybin Act," 2025 Regular Session. https://www.nmlegis.gov/Sessions/25 Regular/bills/senate/SB0219.HTML
³ Oregon Health Authority. "Oregon Psilocybin Services: Access Psilocybin Services." https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-access-psilocybin-services.aspx
⁴ New Mexico Department of Health. Public comment on proposed rule 7.35.3 NMAC. September 16, 2026. https://www.nmhealth.org/publication/view/rules/9828/ | New Mexico Department of Health. Joint public comment on proposed rule 7.35.3 NMAC. https://www.nmhealth.org/publication/view/rules/9847/
⁵ Source New Mexico. "New Mexico psilocybin program opens permitting applications for psychedelic mushroom producers." August 27, 2026. https://sourcenm.com/2026/08/27/new-mexico-psilocybin-program-opens-permitting-applications-for-psychedelic-mushroom-producers/
⁶ New Mexico Department of Health. "Proposed Adoption of New Rule 7.35.2 NMAC" (psilocybin producers and testing laboratories). March 2026. https://www.nmhealth.org/publication/view/rules/9692/
⁷ Peskuski, C. "New Mexico medical psilocybin rules could limit patient access." Albuquerque Journal (opinion). September 26, 2026. https://www.abqjournal.com/opinion/opinion-medical-psilocybin-on-track-to-what/3126348
⁸ Szarpak, L., Pruc, M., Swieczkowski, D., et al. "Cardiovascular safety of psilocybin in psychiatric practice: a narrative review." European Journal of Clinical Pharmacology 82, 223 (2026). DOI: 10.1007/s00228-026-04151-2. https://link.springer.com/article/10.1007/s00228-026-04151-2
⁹ Congress.gov. "S.4220, Veterans Health Administration Novel Therapeutics Preparedness Act, 119th Congress (2025-2026): Actions." https://www.congress.gov/bill/119th-congress/senate-bill/4220/all-actions-without-amendments | Bill text: https://www.govinfo.gov/app/details/BILLS-119s4220is
¹⁰ Marijuana Moment. "American Legion Endorses Psychedelics Bill In Congress, Highlighting Potential Benefits For Military Veterans." September 17, 2026. https://www.marijuanamoment.net/american-legion-endorses-psychedelics-bill-in-congress-highlighting-potential-benefits-for-military-veterans
¹¹ Oregon Health Authority. "OHA statement: Agency not moving forward with proposed fee increases for psilocybin licensees." September 22, 2026. https://www.oregon.gov/oha/erd/pages/oha-statement-agency-not-moving-forward-with-proposed-fee-increases-for-psilocybin-licensees-09.22.2026.aspx
¹² Definium Therapeutics. "Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results." September 8, 2026. https://ir.definiumtx.com/news-events/press-releases/detail/247/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally-disintegrating-tablet-odt-in-major-depressive-disorder-mdd-following-positive-phase-3-results
¹³ HHS. "HHS Announces Key Leadership Selections at FDA." September 8, 2026. https://www.hhs.gov/press-room/hhs-announces-key-fda-leadership-selections.html | RAPS. "FDA names permanent CDER, CBER directors, new deputy commissioner for AI." September 2026. https://www.raps.org/resource/fda-names-permanent-cder-cber-directors-new-deputy-commissioner-for-ai.html
The Rose Hill Review
Advancing the development of novel psychedelic-based therapeutics.
Get this analysis every week, in your inbox.
Clinical science, veteran data, and honest coverage of psychedelic medicine, every Tuesday.